{"subsection_name": "Money &amp; Policy", "pub_date": "2011-10-20T14:24:35Z", "byline": {"original": "By BRUCE JAPSEN", "person": [{"lastname": "JAPSEN", "organization": "", "rank": 1, "role": "reported", "firstname": "Bruce"}]}, "abstract": "In the third quarter, Abbott's Niaspan failed to show the double-digit sales increases that the drug had previously generated.", "word_count": "407", "print_page": null, "news_desk": null, "snippet": "In the third quarter, Abbott's Niaspan failed to show the double-digit sales increases that the drug had previously generated.", "multimedia": [], "source": "The New York Times", "blog": [], "keywords": [], "type_of_material": "Blog", "lead_paragraph": null, "web_url": "http://prescriptions.blogs.nytimes.com/2011/10/20/cholesterol-drug-sales-slip-after-study/", "section_name": "Health", "headline": {"main": "Cholesterol Drug Sales Slip After Study", "kicker": "Prescriptions Blog"}, "slideshow_credits": null, "_id": "54f3b7fa38f0d84018917810", "document_type": "blogpost"}